Zoetis Inc. SEC filings ZTS

Zoetis Inc. has 1,002 filings in SEC EDGAR's recent list, going back to Feb 19, 2020. Its latest annual report, Form ARS, was filed on Apr 8, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 13, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on December 31.

Zoetis Inc. SEC filings
Form Description Filed Period
11-K Employee savings plan report Jun 22, 2026 Dec 31, 2025
SD Specialized disclosure (conflict minerals) May 28, 2026 —
11-K Employee savings plan report Jun 23, 2025 Dec 31, 2024
SD Specialized disclosure (conflict minerals) Jun 2, 2025 —
11-K Employee savings plan report Jun 26, 2024 Dec 31, 2023
SD Specialized disclosure (conflict minerals) May 30, 2024 —
11-K Employee savings plan report Jun 26, 2023 Dec 31, 2022
SD Specialized disclosure (conflict minerals) May 30, 2023 —
PX14A6G Filing Apr 12, 2023 —
UPLOAD Letter from the SEC Oct 3, 2022 —
CORRESP Letter to the SEC Sep 8, 2022 —
UPLOAD Letter from the SEC Sep 8, 2022 —
11-K Employee savings plan report Jun 21, 2022 Dec 31, 2021
SD Specialized disclosure (conflict minerals) May 27, 2022 —
11-K Employee savings plan report Jun 24, 2021 Dec 31, 2020
SD Specialized disclosure (conflict minerals) May 28, 2021 —
11-K Employee savings plan report Jun 26, 2020 Dec 31, 2019
SD Specialized disclosure (conflict minerals) May 29, 2020 —

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ZTS (NYSE)
Fiscal year ends
December 31
Headquarters
Parsippany, NJ
SEC filer status
Large accelerated filer
SEC CIK
1555280

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.